Abstract
Recent comprehensive genetic studies revealed numerous genetic aberrations underlying a group of high-risk leukemias that share a specific activated kinase gene expression pattern. These ALLs were first recognized by the expression profile similar to that of Philadelphia chromosome-positive ALL and currently can be sub-classified by the main aberrantly activated kinase in the leukemic cells. We herein review the biological mechanisms and diagnostic and clinical challenges presented by these leukemias.
Keywords:
BCR-ABL-like ALL; JAK inhibitors; Kinase-driven ALL; Ph-like ALL; Tyrosine kinase inhibitors.
Copyright © 2016 Elsevier Ltd. All rights reserved.
Publication types
-
Review
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Animals
-
Fusion Proteins, bcr-abl / genetics*
-
Fusion Proteins, bcr-abl / metabolism
-
Gene Deletion
-
Genetic Association Studies
-
Genetic Predisposition to Disease
-
Humans
-
Ikaros Transcription Factor / genetics
-
Ikaros Transcription Factor / metabolism
-
Janus Kinases / metabolism
-
Phenotype
-
Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis
-
Precursor Cell Lymphoblastic Leukemia-Lymphoma / etiology*
-
Precursor Cell Lymphoblastic Leukemia-Lymphoma / metabolism*
-
Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy
-
STAT Transcription Factors / metabolism
-
Signal Transduction
Substances
-
STAT Transcription Factors
-
Ikaros Transcription Factor
-
Fusion Proteins, bcr-abl
-
Janus Kinases